BCG downregulates PD1 and PD-L1 expression in bladder cancer cells co-cultivated with peripheral blood mononuclear cells

• Päätekijät: Katia R. M. Leite (Tekijä), Denis Reis Morais (Tekijä), Cristina Massoco (Tekijä), Sabrina T. Reis (Tekijä), Nayara I. Viana (Tekijä), Iran A. Silva (Tekijä), Vanessa Guimaraes (Tekijä), Ruan Pimenta (Tekijä), Gabriel Arantes (Tekijä), Miguel Srougi (Tekijä), Willian Carlos Nahas (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: BMC, 2022-10-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract Purpose BCG is the standard of care to treat high risk non-muscle invasive bladder cancer (NMIBC), reducing recurrence. PD-L1 is a ligand of the co-inhibitory receptor PD1 that has been shown to be expressed by tumor cells of distinct origin related to unfavorable prognosis. The development...